Literature DB >> 20874010

Varicella-zoster virus human ganglionic latency: a current summary.

Peter G E Kennedy1, Randall J Cohrs.   

Abstract

Varicella-zoster virus (VZV) is a ubiquitous human herpes virus typically acquired in childhood when it causes varicella (chickenpox), following which the virus establishes a latent infection in trigeminal and dorsal root ganglia that lasts for the life of the individual. VZV subsequently reactivates, spontaneously or after specific triggering factors, to cause herpes zoster (shingles), which may be complicated by postherpetic neuralgia and several other neurological complications including vasculopathy. Our understanding of VZV latency lags behind our knowledge of herpes simplex virus type 1 (HSV-1) latency primarily due to the difficulty in propagating the virus to high titers in a cell-free state, and the lack of a suitable small-animal model for studying virus latency and reactivation. It is now established beyond doubt that latent VZV is predominantly located in human ganglionic neurons. Virus gene transcription during latency is epigenetically regulated, and appears to be restricted to expression of at least six genes, with expression of gene 63 being the hallmark of latency. However, viral gene transcription may be more extensive than previously thought. There is also evidence for several VZV genes being expressed at the protein level, including VZV gene 63-encoded protein, but recent evidence suggests that this may not be a common event. The nature and extent of the chronic inflammatory response in latently infected ganglia is also of current interest. There remain several questions concerning the VZV latency process that still need to be resolved unambiguously and it is likely that this will require the use of newly developed molecular technologies, such as GeXPS multiplex polymerase chain reaction (PCR) for virus transcriptional analysis and ChIP-seq to study the epigenetic of latent virus genome ( Liu et al, 2010 , BMC Biol 8: 56).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20874010     DOI: 10.1007/BF03210846

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   3.739


  61 in total

1.  Varicella-zoster virus ORF63 inhibits apoptosis of primary human neurons.

Authors:  Chantelle Hood; Anthony L Cunningham; Barry Slobedman; Ann M Arvin; Marvin H Sommer; Paul R Kinchington; Allison Abendroth
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Latent Varicella-zoster virus in human dorsal root ganglia.

Authors:  P G Kennedy; E Grinfeld; J W Gow
Journal:  Virology       Date:  1999-06-05       Impact factor: 3.616

3.  Patterns of gene expression and sites of latency in human nerve ganglia are different for varicella-zoster and herpes simplex viruses.

Authors:  K D Croen; J M Ostrove; L J Dragovic; S E Straus
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

4.  Disruption of the varicella-zoster virus dUTPase and the adjacent ORF9A gene results in impaired growth and reduced syncytia formation in vitro.

Authors:  J Ross; M Williams; J I Cohen
Journal:  Virology       Date:  1997-08-04       Impact factor: 3.616

5.  Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster.

Authors:  Jason J Chen; Zhenglun Zhu; Anne A Gershon; Michael D Gershon
Journal:  Cell       Date:  2004-12-29       Impact factor: 41.582

6.  Array analysis of viral gene transcription during lytic infection of cells in tissue culture with Varicella-Zoster virus.

Authors:  Randall J Cohrs; Michael P Hurley; Donald H Gilden
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

7.  Red-mediated transposition and final release of the mini-F vector of a cloned infectious herpesvirus genome.

Authors:  Felix Wussow; Helmut Fickenscher; B Karsten Tischer
Journal:  PLoS One       Date:  2009-12-04       Impact factor: 3.240

8.  Aberrant intracellular localization of Varicella-Zoster virus regulatory proteins during latency.

Authors:  O Lungu; C A Panagiotidis; P W Annunziato; A A Gershon; S J Silverstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

Review 9.  Varicella-zoster virus latency in human ganglia.

Authors:  Peter G E Kennedy
Journal:  Rev Med Virol       Date:  2002 Sep-Oct       Impact factor: 6.989

Review 10.  A proposal for a common nomenclature for viral clades that form the species varicella-zoster virus: summary of VZV Nomenclature Meeting 2008, Barts and the London School of Medicine and Dentistry, 24-25 July 2008.

Authors:  Judith Breuer; Charles Grose; Peter Norberg; Graham Tipples; D Scott Schmid
Journal:  J Gen Virol       Date:  2010-01-13       Impact factor: 3.891

View more
  29 in total

1.  A sequence within the varicella-zoster virus (VZV) OriS is a negative regulator of DNA replication and is bound by a protein complex containing the VZV ORF29 protein.

Authors:  Mohamed I Khalil; Ann Arvin; Jeremy Jones; William T Ruyechan
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  VZV uveoretino meningitis following dental treatment.

Authors:  Sanjeev Rajakulendran; Smriti Pathak; Yen F Tai; Frances Sanderson; Nicholas W S Davies
Journal:  J Neurovirol       Date:  2013-03-19       Impact factor: 2.643

Review 3.  Immunosenescence: the Role of Aging in the Predisposition to Neuro-Infectious Complications Arising from the Treatment of Multiple Sclerosis.

Authors:  Elena Grebenciucova; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08       Impact factor: 5.081

4.  Simian varicella virus gene expression during acute and latent infection of rhesus macaques.

Authors:  Christine Meyer; Amelia Kerns; Alex Barron; Craig Kreklywich; Daniel N Streblow; Ilhem Messaoudi
Journal:  J Neurovirol       Date:  2011-11-04       Impact factor: 2.643

5.  Zoster duplex: a clinical report and etiologic analysis.

Authors:  Feng Zhang; Jin Zhou
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 6.  A comparison of herpes simplex virus type 1 and varicella-zoster virus latency and reactivation.

Authors:  Peter G E Kennedy; Joel Rovnak; Hussain Badani; Randall J Cohrs
Journal:  J Gen Virol       Date:  2015-03-20       Impact factor: 3.891

Review 7.  Pathogenesis and current approaches to control of varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 8.  Varicella zoster vaccines and their implications for development of HSV vaccines.

Authors:  Anne A Gershon
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

9.  Varicella-zoster virus open reading frame 48 encodes an active nuclease.

Authors:  Niklaus H Mueller; Don Gilden; Randall J Cohrs
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

Review 10.  Issues in the Treatment of Neurological Conditions Caused by Reactivation of Varicella Zoster Virus (VZV).

Authors:  Peter G E Kennedy
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.